T 0821/09 (Medical use of dsRNA/CANCER RESEARCH TECHNOLOGY) of 18.12.2014
- European Case Law Identifier
- ECLI:EP:BA:2014:T082109.20141218
- Date of decision
- 18 December 2014
- Case number
- T 0821/09
- Petition for review of
- -
- Application number
- 00976188.3
- IPC class
- C12N 15/63
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Inhibiting gene expression with dsRNA
- Applicant name
- Cancer Research Technology Limited
- Opponent name
- Sanofi-Aventis Deutschland GmbH
Quark Biotech, Inc.
Sirna Therapeutics
Nucleonics, Inc.
Silence Therapeutics AG
Glaxo Group Limited - Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54(2)European Patent Convention Art 54(3)European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13
- Keywords
- New main request and first auxiliary request - not admitted
Second auxiliary request - admitted
Compliance with Articles 123(2)(3), 84 and 83 - (yes)
Novelty - (yes)
Remittal - (yes) - Catchword
- -
- Cited cases
- T 0524/01
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution on the basis of the claims 1 to 4 according to the second auxiliary request filed during the oral proceedings.